# EDGAR Filing Document

**Accession Number:** 0001813814
**File Stem:** 0000950170-25-100902
**Filing Date:** 2025-7
**Character Count:** 56003
**Document Hash:** 31adfde887286a150864a5089b4897a4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-100902.hdr.sgml**: 20250731

**ACCESSION NUMBER**: 0000950170-25-100902

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 41

**CONFORMED PERIOD OF REPORT**: 20250731

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250731

**DATE AS OF CHANGE**: 20250731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mind Medicine (MindMed) Inc.
- **CENTRAL INDEX KEY:** 0001813814
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40360
- **FILM NUMBER:** 251171776

**BUSINESS ADDRESS:**
- **STREET 1:** ONE WORLD TRADE CENTER
- **STREET 2:** SUITE 8500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10007
- **BUSINESS PHONE:** 212-220-6633

**MAIL ADDRESS:**
- **STREET 1:** ONE WORLD TRADE CENTER
- **STREET 2:** SUITE 8500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10007

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## **FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** July 31, 2025<br>

------

Mind Medicine (MindMed) Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| British Columbia | 001-40360 | 98-1582438 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| One World Trade Center<br>Suite 8500 |  |  |
| New York**,** New York |  | 10007 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (212) 220-6633<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Shares | MNMD | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## **Item 2.02 Results of Operations and Financial Condition.** 
On July 31, 2025, Mind Medicine (MindMed) Inc. (the "Company") issued a press release announcing its financial results for its second quarter ended June 30, 2025, as well as information regarding a conference call to discuss these financial results and the Company's recent corporate highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

The information contained in this Item 2.02 of this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

## **Item 8.01 Other Events.** 
On July 31, 2025, the Company posted an updated corporate presentation on its website. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference in this Item 8.01.

## **Item 9.01 Financial Statements and Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [<u>Press Release, dated July 31, 2025</u>](mnmd-ex99_1.htm) |
| 99.2 | [<u>Corporate Presentation, posted July 31, 2025</u>](mnmd-ex99_2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | MIND MEDICINE (MINDMED) INC. |
| Date: | July 31, 2025 | By:  | /s/ Robert Barrow |
|  |  |  | Name: Robert Barrow<br>Title: Chief Executive Officer |

---

------

## Exhibit 99.1

**Exhibit 99.1**

![img158589805_0.jpg](img158589805_0.jpg)

**MindMed Reports Q2 2025 Financial Results and Business Updates**

*--Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)--*

*--Data from the Phase 3 Voyage trial in GAD anticipated in 1H 2026 and data from the Phase 3 Panorama trial in GAD and Phase 3 Emerge trial in MDD anticipated in 2H 2026--*

*--Strengthened leadership team with appointment of Brandi L. Roberts as Chief Financial Officer--* 

*--Conference call scheduled today at 4:30 p.m. EDT--*

NEW YORK, July 31, 2025 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its second quarter 2025 financial results and provided an update on business highlights.

"We continue making significant progress across all three of our pivotal Phase 3 trials evaluating MM120 ODT in GAD and MDD, with ongoing enthusiasm from both trial sites and participants driving strong enrollment," said Rob Barrow, Chief Executive Officer of MindMed. "We remain on track to report topline data from our Phase 3 Voyage trial in the first half of 2026, followed by Panorama and Emerge in the second half of the year. In parallel, we are advancing our commercial strategy and have continued to strengthen our leadership team with the appointment of Brandi Roberts as Chief Financial Officer. With our clearly defined regulatory strategy, disciplined operational execution, and strong balance sheet, we are well-positioned to advance MM120 ODT as a potential best-in-class therapeutic option for the treatment of GAD and MDD."

**<u>Business Highlights</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Progressing Pivotal Trials: Strong enrollment continues across all three MM120 ODT Phase 3 trials: Voyage and Panorama in GAD and Emerge in MDD. The continued execution reinforces the Company's targeted trial timelines and progress in preparing for a potential NDA filing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Strengthened Leadership for Growth: Appointed Brandi L. Roberts as Chief Financial Officer. Ms. Roberts brings more than 25 years of financial leadership experience within the life sciences industry. As a member of the executive team, she leads all aspects of the Company's financial strategy, capital planning, accounting, investor relations and information technology.

**<u>Program Status and Anticipated Milestones</u>**

**MM120 ODT (lysergide D-tartrate) for GAD** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Enrollment is on track in the Phase 3 Voyage study of MM120 ODT for the treatment of GAD. Voyage is expected to enroll approximately 200 participants in the U.S. who will be randomized 1:1 to receive MM120 ODT 100 µg or placebo. Topline data from the 12-week double-blind period (Part A) is anticipated in the first half of 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Enrollment is on track in the Panorama study, the Company's second Phase 3 study of MM120 ODT for the treatment of GAD. Panorama is expected to enroll approximately 250 participants (randomized 2:1:2 to receive MM120 ODT 100 µg, MM120 ODT 50 µg or placebo) in the U.S. and Europe. Topline data from the 12-week double-blind period (Part A) is anticipated in the second half of 2026.

------

**MM120 (lysergide D-tartrate) for MDD**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Enrollment is on track in the Phase 3 Emerge study of M120 ODT for the treatment of MDD. Emerge is expected to enroll 140 participants (randomized 1:1 to receive MM120 ODT 100 µg or placebo). Topline data from the 12-week double-blinded period (Part A) is anticipated in the second half of 2026. The Company expects to conduct a second Phase 3 registrational study in MDD, with the study design and timing to be informed by the progress of Emerge and additional regulatory discussions.

**MM402 (R(-)-MDMA) for Autism Spectrum Disorder (ASD)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Completed a Phase 1 study of MM402, a single-ascending dose study in adult healthy volunteers. The study characterized the tolerability, pharmacokinetics and pharmacodynamics of MM402. The Company expects to initiate further studies of MM402 to assess its potential efficacy for the treatment of ASD.

**<u>Second Quarter 2025 Financial Results</u>**

*Cash Balance.* As of June 30, 2025, MindMed had cash, cash equivalents and investments totaling $237.9 million compared to $245.5 million as of March 31, 2025.

Based on the Company's current operating plan and anticipated R&D milestones, the Company believes that its cash, cash equivalents and investments as of June 30, 2025 will be sufficient to fund the Company's operations into 2027 and at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD.

*Research and Development (R&D).* R&D expenses were $29.8 million for the quarter ended June 30, 2025, compared to $14.6 million for the quarter ended June 30, 2024, an increase of $15.2 million. The net increase of $15.2 million was primarily related to increases of $14.5 million related to our MM120 ODT program, $1.5 million in internal personnel costs as a result of increased headcount, and $0.2 million related to preclinical activities, offset by a decrease of $1.0 million in MM402 program expenses based on the timing of studies.

*General and Administrative (G&A).* G&A expenses were $11.1 million for the quarter ended June 30, 2025, compared to $9.8 million for the quarter ended June 30, 2024, an increase of $1.3 million. The increase was primarily related to increases in personnel costs as a result of increased headcount.

*Net Loss.* Net loss for the quarter ended June 30, 2025, was $42.7 million, compared to $5.9 million for the same period in 2024, a decrease of $36.8 million. The decrease was primarily due to increases in operating expenses of $16.4 million, changes in the fair value of warrants issued in our September 2022 underwritten offering of $15.6 million, the absence of a $2.5 million gain on extinguishment of contribution payable from 2024 and increased interest expense related primarily to the amendment of our credit facility of $1.8 million.

**<u>Conference Call and Webcast Reminder</u>**

MindMed management will host a webcast at 4:30 p.m. EDT today to provide a corporate update and review the Company's second quarter 2025 financial results, and business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

**About MM120 Orally Disintegrating Tablet (ODT)**

MM120 ODT (lysergide D-tartrate or LSD) is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics which acts as a partial agonist at human serotonin-2A (5-HT2A) receptors. MM120 ODT is MindMed's proprietary and pharmaceutically optimized form of LSD. MM120 ODT is an advanced formulation incorporating Catalent's Zydis® ODT fast-dissolve technology which has a unique clinical profile with more rapid absorption, improved bioavailability and reduced gastrointestinal side effects. MindMed is developing MM120, the

------

tartrate salt form of lysergide, for generalized anxiety disorder (GAD), major depressive disorder (MDD), and is exploring its potential applications in other serious brain health disorders.

**About MM402**

MM402 is the Company's proprietary form of R(-)-MDMA (rectus-3,4-methylenedioxymethamphetamine), being developed for the treatment of core symptoms of Autism Spectrum Disorder (ASD). MDMA is a synthetic molecule that is often referred to as an empathogen because it is reported to increase feelings of connectedness and compassion. Preclinical studies of R(-)-MDMA demonstrate its acute pro-social and empathogenic effects, while its diminished dopaminergic activity suggest that it has the potential to exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability compared to racemic MDMA or the S(+)-enantiomer.

**About MindMed**

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.

**Forward-Looking Statements** 

Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding the Company's anticipated topline readout (Part A results) for the Phase 3 Voyage study of MM120 ODT in GAD in the first half of 2026; the Company's anticipated topline readout (Part A results) for the Phase 3 Panorama study for MM120 ODT in GAD in the second half of 2026; the Company's anticipated topline readout (Part A results) for the Phase 3 Emerge study for MM120 ODT in MDD in the second half of 2026; the Company's plans to conduct a second Phase 3 study in MDD; the Company's expectations regarding the enrollment for each of the Voyage, Panorama and Emerge studies; the Company's beliefs regarding potential benefits of its product candidates; the Company's expectation to conduct further studies of MM402; the Company's expectation that its cash, cash equivalents and investments will fund operations into 2027; the Company's expectation that its cash runway will extend at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD; and potential additional indications for MM120 ODT and MM402. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; compliance with laws and regulations; legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of our product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.; difficulty associated with research and development; risks associated with clinical studies or studies; heightened regulatory scrutiny; early stage product development; clinical study risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; ability to maintain effective patent rights and other intellectual property protection; as well as those risk factors discussed or referred to herein and the risks, uncertainties and other factors described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 under headings such as "Special Note Regarding Forward-Looking Statements," and "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Except as required by law, the Company undertakes no duty or obligation to update any

------

forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.

**For Media:** <u>media@mindmed.co</u>

**For Investors:** <u>ir@mindmed.co</u>

------

**Mind Medicine (MindMed) Inc.** 

**Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
| **(in thousands, except share amounts)** | **June 30, 2025<br>(unaudited)** | **December 31, 2024** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $33392 | $273741 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 149601 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid and other current assets | 6143 | 7879 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 189136 | 281620 |
| Long-term investments | 54863 |  |
| Goodwill | 19918 | 19918 |
| Other non-current assets | 1174 | 613 |
| Total assets | $265091 | $302151 |
| **Liabilities and Shareholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $4216 | $2010 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 14797 | 12829 |
| &nbsp;&nbsp;&nbsp;&nbsp;2022 USD Financing Warrants | 18944 | 24010 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 37957 | 38849 |
| Credit facility, long-term | 41191 | 21854 |
| Other non-current liabilities | 543 |  |
| Total liabilities | 79691 | 60703 |
| Commitments and contingencies |  |  |
| Shareholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common shares, no par value, unlimited authorized as of June 30, 2025 and December 31, 2024; 75,803,251 and 75,100,763 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 649564 | 639508 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 807 | 819 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (464971) | (398879) |
| Total shareholders' equity | 185400 | 241448 |
| Total liabilities and shareholders' equity | $265091 | $302151 |

---

------

**Mind Medicine (MindMed) Inc.**

**Consolidated Statements of Operations and Comprehensive Loss**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| **(in thousands, except share and per share amounts)** | **2025** | **2024** | **2025** | **2024** |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | $29809 | $14645 | $53166 | $26350 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 11094 | 9813 | 19896 | 20312 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 40903 | 24458 | 73062 | 46662 |
| Loss from operations | (40903) | (24458) | (73062) | (46662) |
| Other income/(expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 2774 | 3116 | 5207 | 4772 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (2338) | (466) | (2940) | (900) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange loss, net | (49) | (32) | (68) | (557) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of 2022 USD Financing Warrants | (2228) | 13445 | 4771 | (19448) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on extinguishment of contribution payable |  | 2541 |  | 2541 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income/(expense) | (1841) | 18604 | 6970 | (13592) |
| Net loss | (42744) | (5854) | (66092) | (60254) |
| Other comprehensive loss |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain on investments | 36 |  | 46 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain/(loss) on foreign currency translation | (31) | (3) | (58) | 490 |
| Comprehensive loss | $(42739) | $(5857) | $(66104) | $(59764) |
| Net loss per common share, basic | $(0.50) | $(0.08) | $(0.78) | $(1.01) |
| Net loss per common share, diluted | $(0.50) | $(0.26) | $(0.81) | $(1.01) |
| Weighted-average common shares, basic | 85347677 | 71912323 | 85208539 | 59886540 |
| Weighted-average common shares, diluted | 85347677 | 75304101 | 87099006 | 59886540 |

---

------

## Exhibit 99.2

![Slide 1](mnmd-ex99_2s1.jpg)

Corporate Presentation August 2025

------

![Slide 2](mnmd-ex99_2s2.jpg)

This presentation (the "Presentation") has been prepared by Mind Medicine (MindMed) Inc. ("MindMed", the "Company", "we", "our" or "us) solely for informational purposes. This Presentation does not constitute an offering of, or a solicitation of an offer to purchase, securities of MindMed and under no circumstances is it to be construed as a prospectus or advertisement or public offering of securities. Any trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of MindMed. Any amounts are in USD unless otherwise noted. MindMed's securities have not been approved or disapproved by the Securities and Exchange Commission (the "SEC") or by any state, provincial or other securities regulatory authority, nor has the SEC or any state, provincial or other securities regulatory authority passed on the accuracy or adequacy of this Presentation. Any representation to the contrary is a criminal offense. Cautionary Note Regarding Forward-Looking Statements This Presentation contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of applicable securities laws and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential", "continue", "budget", "scheduled", "forecasts", "intends", "anticipates", "projects" or the negative thereof or similar variations. Forward-looking statements in this Presentation include, but are not limited to, statements regarding the anticipated design, timing, progress and results of our investigational programs for MM120, a proprietary, pharmaceutically optimized form of lysergide D-tartrate (including the anticipated topline readouts for the Voyage, Panorama and Emerge studies), MM402, also referred to as R(-)-MDMA, and any other product candidates; the success and timing of our development activities; the success and timing of our planned clinical trials; our ability to meet the milestones set forth herein; the likelihood of success of any clinical trials or of obtaining FDA or other regulatory approvals; our beliefs regarding potential benefits of our product candidates; opinions of potential providers regarding our product candidates, if approved and commercialized; our ability to maximize operational efficiencies through our trial designs; strategies to address drug class methodological considerations; our cash runway funding operations into 2027 based on our current operating plan and anticipated research and development milestones and at least 12 months beyond first Phase 3 topline data readout in GAD; our pre-launch strategy; the potential commercial opportunity for MM120, if approved, including total addressable market; the potential delivery model for MM120, if approved; the potential for the markets that we are anticipating to access and protection of our intellectual property. There are numerous risks and uncertainties that could cause actual results, plans and objectives to differ materially from those expressed in forward-looking statements, including history of negative cash flows, limited operating history, incurrence of future losses, availability of additional capital, compliance with laws and regulations, difficulty associated with research and development, risks associated with clinical trials or studies, heightened regulatory scrutiny, early stage product development, clinical trial risks, regulatory approval processes, novelty of the psychedelic inspired medicines industry, our ability to maintain effective patent rights and other intellectual property protection for our product candidates, our expectations regarding the size of the eligible patient populations for our lead product candidates, if approved and commercialized; our ability to identify third-party treatment sites to conduct our trials and our ability to identify and train appropriate qualified healthcare practitioners to administer our treatments; the pricing, coverage and reimbursement of our lead product candidates, if approved and commercialized; the rate and degree of market acceptance and clinical utility of our lead product candidates, in particular, and controlled substances, in general; as well as those risk factors described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 under headings such as "Special Note Regarding Forward-Looking Statements," and "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Any forward-looking statement made by MindMed in this Presentation is based only on information currently available to the Company and speaks only as of the date on which it is made. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this Presentation as a result of new information, future events, changes in expectations or otherwise. Cautionary Note Regarding Regulatory Matters The United States federal government regulates drugs through the Controlled Substances Act. MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate and MM402, or R(-)-MDMA, is our proprietary form of the R-enantiomer of MDMA (3,4-methylenedioxymethamphetamine). Lysergide and MDMA are Schedule I substances under the Controlled Substances Act. While the Company is focused on programs using psychedelic or hallucinogenic compounds and non-hallucinogenic derivatives of these compounds, including in its MM120, MM402 and other product candidates, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances in the jurisdictions in which it operates. The Company is a neuro-pharmaceutical drug development company and does not deal with psychedelic or hallucinogenic substances except within laboratory and clinical trial settings conducted within approved regulatory frameworks. The Company's products will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed. Market and Industry Data This Presentation includes market and industry data that has been obtained from third party sources, including industry publications. MindMed believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MindMed has not independently verified any of the data from third party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article. MindMed does not make any representation as to the accuracy of such information. Disclaimer Corporate Presentation \| August 2025

------

![Slide 3](mnmd-ex99_2s3.jpg)

Corporate Presentation \| August 2025 MindMed: Transformational Innovation for Brain Health Strategic Focus on GAD and MDD The two largest drivers of psychiatric disease burden Late-Stage Pipeline Comprehensive Intellectual Property Strategy MM120 ODT: lead clinical program in three Phase 3 studies Three Phase 3 readouts anticipated in 2026 + potential billion-dollar commercial opportunities in GAD and MDD MM120 ODT patents issued covering pharmaceutical formulation, methods of manufacturing and treatment Cash, cash equivalents and investments of $237.9 million as of June 30, 2025 Cash runway expected to extend into 2027 and at least 12 months beyond first Phase 3 topline data readout in GAD1 Strong Financial Position Experienced Management Team Proven track record in developing and commercializing novel CNS therapies The Company's cash, cash equivalents and investments of $237.9 million as of June 30, 2025, expected to fund operations into 2027 and at least 12 months beyond first Phase 3 topline data readout in GAD, based on our current operating plan and anticipated R&D milestones. GAD: generalized anxiety disorder; MDD: major depressive disorder; ODT: orally disintegrating tablet

------

![Slide 4](mnmd-ex99_2s4.jpg)

2025 On Track and Executing MM120-300 for GAD Phase 3 topline readout 1H 2026 ANTICIPATED MILESTONES MM120-301 for GAD Phase 3 topline readout 2H 2026 MM120-310 for MDD Phase 3 topline readout 2H 2026

------

![Slide 5](mnmd-ex99_2s5.jpg)

2024 1H2025 2H2025 1H2026 2H2026 MM120-310 for MDD Phase 3 Topline Readout MM120-301 for GAD Phase 3 Topline Readout Cash runway expected to extend into 2027 and at least 12 months beyond first Phase 3 topline data readout in GAD1 $250 million in equity investment Initiation of Phase 3 program for MM120 ODT in GAD (first patient dosed in Phase 3 Voyage study) MM120 Phase 2b results presented at APA Annual Meeting MM120 granted breakthrough designation by U.S. FDA Successful End-of-Phase 2 meeting with U.S. FDA supporting pivotal trial plans MM120 ODT patents issued covering pharmaceutical formulation, methods of manufacturing and treatment; patent life through 2041 MM120 ODT awarded Innovation Passport by the U.K. MHRA Corporate Presentation \| August 2025 Strong Execution Driving Upcoming Milestones The Company's cash, cash equivalents and investments of $237.9 million as of June 30, 2025, expected to fund operations into 2027 and at least 12 months beyond first Phase 3 topline data readout in GAD, based on our current operating plan and anticipated R&D milestones. GAD: generalized anxiety disorder; MDD: major depressive disorder; APA: American Psychiatric Association; ODT: orally disintegrating tablet; U.K. MHRA: United Kingdom Medicines and Healthcare Products Regulatory Agency First patient dosed in 2nd Phase 3 GAD Study - Panorama First patient dosed in Phase 3 MDD Study - Emerge MM120-300 for GAD Phase 3 Topline Readout

------

![Slide 6](mnmd-ex99_2s6.jpg)

Advancing Our Pipeline with Broad Therapeutic Potential Full trial details and clinicaltrials.gov links available at mindmed.co/clinical-digital-trials/ Studies in exploration and/or planning stage. LSD: lysergide; ODT: orally disintegrating tablet; R(-)-MDMA: rectus-3,4-methylenedioxymethamphetamine Corporate Presentation \| August 2025 Product Candidate Indication Preclinical Phase 1 Phase 2 Pivotal / Phase 3 Registration MM120 ODT (Lysergide D-tartrate) Generalized Anxiety Disorder (GAD)1 Generalized Anxiety Disorder (GAD) Major Depressive Disorder (MDD)1 Additional Indication(s)2 Additional Psychiatric Indication MM402 (R(-)-MDMA) Autism Spectrum Disorder (ASD)1,2 Autism Spectrum Disorder (ASD)

------

![Slide 7](mnmd-ex99_2s7.jpg)

Corporate Presentation \| August 2025 Critical Gaps in Care Demand Innovation Fast onset Single intermittent administration Favorable tolerability 26 million U.S. adults live with GAD1 Last FDA approval in 2007 50% of patients failed by first-line pharmacological treatments2 Co-occurring MDD and GAD is associated with increases in mean annual per patient inpatient visits, office visits, emergency department visits, annual drug costs, and total medical costs7,8 41 million U.S. adults live with MDD1 2/3 do not achieve remission after 1st line therapy3,4 Patients who receive treatment: 30% failed by 2+ lines of therapy5,6 MDD >50-70% Overlap GAD High remission rates Durable response Restores neural pathways Desired Future State of Treatment GAD: generalized anxiety disorder; MDD: major depressive disorder 1. Ringeisen, H., et al. (2023). Mental and Substance Use Disorders Prevalence Study (MDPS): Findings Report. RTI International and current U.S. Census data and internal company estimates; 2. Ansara ED. Management of treatment-resistant generalized anxiety disorder. Ment Health Clin. 2020 Nov 5;10(6):326-334; 3. Kolovos S, et al. The effect of treatment as usual on major depressive disorder: a meta-analysis. J Affect Disord. 2017;210:72-81; 4. Rush AJ, et al; STAR\*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242; 5. Zhdanava M, et al. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. J Clin Psychiatry. 2021 Mar 16;82(2):20m13699; 6. McIntyre RS, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023 Oct;22(3):394-412; 7. Kessler RC, et al. Epidemiol Psychiatry Sci 2015; 24:210–226; 8. Armbrecht E, et al. J Multidiscip Healthc. 2021 Apr 23;14:887-896.

------

![Slide 8](mnmd-ex99_2s8.jpg)

Psychedelics: A Welcome Breakthrough for Providers Psychiatrists and Psychiatry Nurse Practitioners Proprietary MindMed Primary Market Research – Key Customer Perceptions Among Spravato® Providers and GAD Prescribers (February 2024). Total Non-Spravato® Providers (n=125), Spravato® Providers (n=50). Spravato® Providers: recommended, referred or prescribed Spravato® treatment and monitored or administered Spravato® treatment, personally or someone in her/his clinic or office. GAD: generalized anxiety disorder; MDD: major depressive disorder; TRD: Treatment Resistant Depression % of Surveyed Providers1 Agree All psychiatric providers2 Interventional psychiatric providers3 Availability of psychedelics for GAD and MDDwill change my approach to treatment I expect psychedelic treatments to radicallytransform the treatment of GAD and MDD 62% 78% 74% 86% Corporate Presentation \| August 2025

------

![Slide 9](mnmd-ex99_2s9.jpg)

Program Overview MM120 ODTLysergide D-tartrate

------

![Slide 10](mnmd-ex99_2s10.jpg)

Clinical Rationale and Mechanism of Action Corporate Presentation \| August 2025

------

![Slide 11](mnmd-ex99_2s11.jpg)

Robust Phase 3 MM120 Development Program Aiming for Broad Label Studies will employ an adaptive design with interim blinded sample size re-estimation based on nuisance parameters (e.g. patient retention rate, variability of primary outcome measure) which allows for an increase of sample size up to 50% to maintain statistical power. Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3 clinical trial protocols. DB: double blind; HAM-A: Hamilton Anxiety Rating Scale; MADRS: Montgomery-Åsberg Depression Rating Scale; ODT: orally disintegrating tablet; OL: open-label; RCT: randomized controlled trial MM120-300 MM120-301 Aligned clinical trial designs across indications maximize operational efficiencies Generalized Anxiety Disorder (GAD) Major Depressive Disorder (MDD) MM120-310 n=2001,2 (1:1 randomization) MM120 ODT vs. Placebo Part A: 12-week DB, RCT Part B: 40-week Extension with OL Treatment n=2501,2 (2:1:2 randomization) MM120 ODT vs. Placebo (including 50 µg control) Part A: 12-week DB, RCT Part B: 40-week Extension with OL Treatment n=1402 (1:1 randomization) MM120 ODT vs. Placebo Part A: 12-week DB, RCT Part B: 40-week Extension with OL Treatment Initiated 4Q2024 Initiated 1Q2025 Initiated 2Q2025 Name TBA MM120-311 Design TBA Primary Endpoint: HAM-A at Week 12 Primary Endpoint: MADRS at Week 6 Corporate Presentation \| August 2025

------

![Slide 12](mnmd-ex99_2s12.jpg)

MM120 Phase 2b Efficacy and Durability Support GAD Phase 3 Trial Plans1,3 1. Study MMED008 internal study documents and calculations. Comparisons to standard of care/other drug classes based on historical comparison not head-to-head comparison trial; 2. HAM-A scores based on ANCOVA LS Mean. in Study MMED008. Effect size based on post hoc calculation using LS Mean change between group and pooled standard deviation of week 12 HAM-A scores between groups; 3. Based on 100 µg dose group; 4. RB Hidalgo, J Psychopharmacol. 2007 Nov;21(8):864-72; 5. p-values not calculated for remission rates between groups. Cohen's d: a standardized effect size measuring the difference between two group means; CGI-S: Clinical Global Impressions – Severity; GAD: generalized anxiety disorder; HAM-A: Hamilton Anxiety Rating Scale Maximum effect size d=0.81 more than double the standard of care1,2,3 0 0.2 0.4 0.6 0.8 0.38 0.36 0.17 0.81 Comparative Effect Sizes in GAD Rapid and durable response after single administration3 Rapid Response & Remission Durable Standalone DrugEffect Limited AdverseEvent (AE) Burden 1.8-point reduction in CGI-S within 24 hours (p<0.0001) 21.9-point improvement on the HAM-A at Week 12 (p=0.003) 48% of participants in remission at Week 125 Favorable tolerability with most AEs on dosing day Observed drug effect without accompanying psychotherapy Cohen's d Corporate Presentation \| August 2025 MM120 100 µg2 Benzodiazepines4 SRIs4 Buspirone4

------

![Slide 13](mnmd-ex99_2s13.jpg)

Primary Outcome: HAM-A Change from Baseline MM120 Phase 2b Showed Statistically & Clinically Significant Improvements on Anxiety and Depression Symptoms1,2 Source: Study MMED008 internal study documents and calculations. Full analysis set population. Based on 100 µg dose group. Based on observed MADRS score at each timepoint. μg: microgram; HAM-A: Hamilton Anxiety Rating Scale; MADRS: Montgomery-Åsberg Depression Rating Scale NOTE: Significance achieved despite study not being powered for these pairwise comparisons. \*p<0.05; \*\*p≤0.01; \*\*\*p≤0.001 Baseline Week 1 Week 2 Week 4 Week 12 \*\*\* \*\*\* \*\*\* \*\* MADRS Change from Baseline \*\* \*\* \* \*\* Change from Baseline2 Week 12: -21.9 points Improvement over Placebo2 Week 12: -7.7 pts, p=0.003 Change from Baseline2,3 Week 12: -18.7 points Improvement over Placebo2,3 Week 12: -6.4 points, p<0.01 Baseline Week 1 Week 2 Week 4 Week 12 Corporate Presentation \| August 2025

------

![Slide 14](mnmd-ex99_2s14.jpg)

MM120 Phase 2b Produced Profound Changes in GAD Severity1 Source: Study MMED008 internal study documents and calculations. Full analysis set population. Response is a 50% or greater improvement on HAM-A score; Remission is a HAM-A score of ≤7; p-values not calculated. μg: microgram; HAM-A: Hamilton Anxiety Rating Scale HAM-A Response and Remission at Week 122 Median HAM-A Through Week 12 HAM-A Severity & Clinical Symptoms Very Severe Symptoms are incapacitating Moderate (15-23) Symptoms are more frequent, with moderate distress or limited interference with usual activities Mild (8-14) Symptoms are infrequent, with no impairment and no more than mild distress Remission (≤7) Symptoms are absent, insignificant, or clearly due to causes other than anxiety Baseline Week 1 Week 2 Week 4 Week 12 Corporate Presentation \| August 2025 Severe (≥24) Symptoms are severe and persistent or result in severe distress or marked impairment in functioning

------

![Slide 15](mnmd-ex99_2s15.jpg)

MM120 Phase 2b was Well-tolerated with Mostly Expected Transient, Mild-to-Moderate Adverse Events on Dosing Day1 Source: Study MMED008 internal study documents and calculations. Safety population. One serious adverse event (SAE) was observed in the 50 µg dose group: panic attack on study day 98 that was deemed not related to treatment. Suicidality assessment based on reported adverse events. Virtually all (99%) adverse events (AEs) were mild-to-moderate in severity Minimal (2.5%) treatment emergent AEs (TEAEs) led to study withdrawal No drug-related serious AEs (SAEs)2 Favorable tolerability profile No SAEs related to study drug No suicidalbehavior orsuicidality signal3 Only SAE was in 50 µg dose group and deemed unrelated 2 AE profile consistent with historical studies and drug class No suicidal or self-injurious behavior No indication of increased suicidality or suicide-related risk ≤2 participants per arm reported suicidal ideation during the study Corporate Presentation \| August 2025

------

![Slide 16](mnmd-ex99_2s16.jpg)

MM120-301 MM120-300 MM120 for GAD \| Two Complementary Pivotal Phase 3 Study Designs1 Studies will employ an adaptive design with interim blinded sample size re-estimation based on nuisance parameters (e.g. patient retention rate, variability of primary outcome measure) to maintain statistical power. Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3 clinical trial protocols. GAD: generalized anxiety disorder; GAD-7: diagnostic tool used to screen for and assess the severity of generalized anxiety disorder; HAM-A: Hamilton Anxiety Rating Scale; ODT: orally disintegrating tablet MM120 ODT 100 µg n=100 Placebo n=100 Part A 12 Week Randomized, Double-Blind Part B 40 Week Extension with Opportunity for Open-Label Treatment MM120 ODT 100 µg n=100 Placebo n=100 MM120 ODT 50 µg n=50 PHASE 3 STUDY Single Dose Potential treatment if HAM-A≥16 Primary Endpoint HAM-A at Week 12 Up to four open-label doses of MM120 ODT 100 µg Single Dose Follow-up Observation GAD-7 (ePRO): biweekly HAM-A (central rater): monthly or when GAD-7≥10 Potential Treatment Eligible for open-label treatment if HAM-A≥16 Corporate Presentation \| August 2025

------

![Slide 17](mnmd-ex99_2s17.jpg)

Primary Endpoint MADRS at Week 6 MM120-311 MM120-310 MM120 for MDD \| Phase 3 Study Design1 Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3 clinical trial protocols. MADRS: Montgomery-Åsberg Depression Rating Scale; MDD: Major Depressive Disorder; ODT: orally disintegrating tablet; PHQ-9: a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression; TBA: to be announced MM120 ODT 100 µg n=70 Placebo n=70 Part A 12 Week Randomized, Double-Blind Part B 40 Week Extension with Opportunity for Open-Label Treatment PHASE 3 STUDY1 Single Dose Potential treatment if MADRS≥20 Up to four open-label doses of MM120 ODT 100 µg [Design TBA] Follow-up Observation PHQ-9 (ePRO): biweekly MADRS (central rater): monthly or when PHQ-9≥10 Potential Treatment Eligible for open-label treatment if MADRS≥20 Corporate Presentation \| August 2025

------

![Slide 18](mnmd-ex99_2s18.jpg)

Today. Regulatory Elements Supporting MM120 ODT NDA Filing Requirements Studies designed to demonstrate standalone drug effect FDA Breakthrough Therapy Designation Phase 2b demonstrated substantial improvement over current therapies1 Phase 3 program in alignment with FDA guidance Phase 3 study design mirrors positive Phase 2b study Corporate Presentation \| August 2025 Study MMED008 internal study documents and calculations. Comparisons to standard of care/other drug classes based on historical comparison not head-to-head comparison trial. GAD: generalized anxiety disorder; NDA: new drug application

------

![Slide 19](mnmd-ex99_2s19.jpg)

Commercial Framework MM120 ODTLSD D-tartrate

------

![Slide 20](mnmd-ex99_2s20.jpg)

Large, Identified, Accessible Opportunity for MM120 ODT High Unmet Need Paradigm Shifting Clinical Profile Efficient Go To Market Strategy Significant Limitations of Existing Treatments MM120 ODT: Potential Best-In-Class Therapy Existing Referral anAdministration Infrastructure Sustained clinical response from a single administration10 Identifiable HCPs and patients suffering from the burden of inadequate treatment Poor efficacy, tolerability, and persistence ~50% Discontinue SSRIs in first 4 mos. in GAD8,9 Rapid onset of effect High response rates High remission rates Durable response Intermittent dosing potentially reduces the risk of adverse long-term effects Slow onset of effect1 Low response and remission rates2-4 Low Rx persistence5 Weight gain6 Sexual dysfunction6 Tolerance and dependence7 Poor Tolerability Poor Efficacy ~7,000 Psychiatrists see >50% of likely MM120 ODT patients11 ~22% Rx persistence at 12 mos. in MDD5 Based on claims data Corporate Presentation \| August 2025 1. Bandelow B et al. World J Biol Psychiatry. 2008;9(4):248-312. 2. Ansara ED. Ment Health Clin. 2020;10(6):326-334. 3. Fagan HA, Baldwin DS. Expert Rev Neurother. 2023;23(6):535-548. 4. Garakani A et al. Front Psychiatry. 2020;11:595584. 5. Keyloun KR et al. CNS Drugs. 2017;31(5):421-432. 6. Cascade E et al. Psychiatry (Edgemont). 2009;6(2):16-18. 7. National Institute for Health and Care Excellence. Anxiety disorders. Quality standard QS53. February 6, 2016. Accessed July 10, 2025. https://www.nice.org.uk/guidance/qs53 8. Bull SA et al. Ann Pharmacother. 2002;36:578-584. 9. Berger A et al. BMC Psychiatry. 2011;11:193. 10. Jacobsen PL et al. American Psychiatric Association Annual Meeting. May 4-8, 2024. New York, NY; 11. Based on internal company estimates. GAD: generalized anxiety disorder; HCP: healthcare provider; MDD: major depressive disorder; ODT: orally disintegrating tablet; Rx: prescription; SSRI: selective serotonin-reuptake inhibitor Anticipate scalable delivery model in diverse care settings Positive practice economics anticipated to expand sites of care

------

![Slide 21](mnmd-ex99_2s21.jpg)

MM120 ODT Clinical Dosing Paradigm with Translatability to EfficientReal-World Delivery1,2 Patients are supported by Dosing Session Monitors (DSMs), healthcare professionals who passively observe and offer comfort care such as assistance with food or restrooms breaks. Psychotherapy is not offered or required but may be added outside a dosing session based on a decision between a provider and patient to support individual goals and needs. Hour 6+ and post session Usual sense of perception is restored Normal activities can resume the next day, including driving Hour 1-6 Transient drug effects, such as visual, emotional and physical effects, vary from person to person Hours 2-3: drug effect reaches maximum intensity Hours 4-6: drug effect starts to resolve 15-30 minutes (time to onset) MM120 ODT dissolves in less than 5 seconds Hour 5-8 Hour 5: DSM will evaluate patient hourly with an end-of-session checklist to determine when the patient can leave safely 5–8-hour duration offers an optimal window for emotional processing and a gentle, predictable, return to baseline Efficient single-visit model with full-session reimbursement streamlines administrative burden Corporate Presentation \| August 2025 Dosing and monitoring paradigm based on Phase 3 clinical protocols Existing coding systems could potentially be applied or be changed for MM120. Reimbursement and coding for MM120 have yet to be established. ODT: orally disintegrating tablet

------

![Slide 22](mnmd-ex99_2s22.jpg)

Corporate Presentation \| August 2025 Positioned to Leverage Existing Delivery Infrastructure, Practice Patterns & Reimbursement Pathways HCP that is licensed to prescribe medications to patients. HCP that is licensed to practice, which may include physicians, clinical psychologists, nurse practitioners, nurses, licensed clinical social workers, licensed family and marriage therapists and others. Existing coding systems could potentially be applied or be changed for MM120. Reimbursement and coding for MM120 have yet to be established. The currently available CPT-III codes (0820T, 0821T, 0822T) describes the in-person continuous monitoring of a psychedelic medication therapy session. CPT: Current Procedural Terminology; ODT: orally disintegrating tablet Office-based or Telehealth Prescriber1 Evaluation & Prescribing Pharmacy MM120 ODT Site of delivery Session Delivery Activity Medical Benefit CPT-I E&M Code (992XX) Pharmacy Benefit J Code & Dispensing Fee Medical Benefit CPT-III Code4 (0820T/0821T/0822T) or CPT-I Service Codes (992XX + 994XX) Stakeholder Reimbursement/Coding3 HCP2 to monitor session

------

![Slide 23](mnmd-ex99_2s23.jpg)

$250 million in equity investment Initiation of Phase 3 program for MM120 ODT in GAD (first patient dosed in Phase 3 Voyage study) MM120 Phase 2b results presented at APA Annual Meeting MM120 granted breakthrough designation by U.S. FDA Successful end-of-phase 2 meeting with U.S. FDA supporting pivotal trial plans MM120 ODT patent issued covering pharmaceutical formulation, methods of manufacturing and treatment; patent life through 2041 MM120 ODT awarded Innovation Passport by the U.K. MHRA Financial Summary & Upcoming Milestones Corporate Presentation \| August 2025 Key Milestones Anticipated Timing GAD Phase 3 topline data 1H 2026 GAD Phase 3 topline data 2H 2026 MDD Phase 3 topline data 2H 2026 Three Phase 3 topline readouts expected in 2026 Potential billion-dollar commercial opportunities in both GAD and MDD Cash, Cash Equivalents & Investments $237.9 million as of June 30, 2025 Credit Facility Up to $120 million ($42 million outstanding) as of June 30, 2025 Shares Outstanding 75.8 million as of June 30, 2025 Second Quarter 2025 Operating Expenses $40.9 million R&D - $29.8 million G&A - $11.1 million MM120 ODT GAD: generalized anxiety disorder; G&A: general & administrative; MDD: major depressive disorder; R&D: research and development

------

![Slide 24](mnmd-ex99_2s24.jpg)

Nasdaq: MNMD

------

![Slide 25](mnmd-ex99_2s25.jpg)

Appendix

------

![Slide 26](mnmd-ex99_2s26.jpg)

MM120-301 250 participants (2:1:2)2 Randomize Screen Dose Follow-Up MM120 ODT 100 µg (n=100)2 MM120 ODT 50 µg (n=50)2 Placebo (n=100)2 MM120-300 200 participants (1:1)2 MM120 ODT 100 µg (n=100)2 Placebo (n=100)2 -30 to -1 1 2 4 8 12 16 20 24 28 32 36 40 44 48 52 Corporate Presentation \| August 2025 MM120 for GAD \| Phase 3 Study Design Leverages Phase 2b Results1 Source: Study MM120-300 and Study MM120-301 internal study documents. Study will employ an adaptive design with interim blinded sample size re-estimation based on nuisance parameters (e.g. patient retention rate, variability of primary outcome measure) allowing for up to 50% more subjects in each arm to maintain statistical power. Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3 clinical trial protocols. μg: microgram; CGI-S: Clinical Global Impressions - Severity; GAD: generalized anxiety disorder; HAM-A: Hamilton Anxiety Rating Scale; ODT: orally disintegrating tablet KEY SECONDARY ENDPOINTS HAM-A at Week 1 CGI-S at Day 2 Time to retreatment / inefficacy SELECT ENTRY CRITERIA Men and Women Ages 18-74 Diagnosis of GAD HAM-A ≥20 Part A 12 Week Randomized, Double-Blind Part B 40 Week Extension with Opportunity for Open-Label Treatment Primary Endpoint: HAM-A at Week 12 PART B ENDPOINTS Safety of repeated treatment Time to retreatment / inefficacy Average treatments per year Response to retreatment MM120-300 & 301 \| Parts A & B

------

![Slide 27](mnmd-ex99_2s27.jpg)

Strategies Addressing Key Drug Class Methodological Considerations AE: adverse event; ECG: electrocardiogram; MOA: mechanism of action; TQT: thorough QT Expectancy Bias & Functional Unblinding Cardiovascular Safety Adverse Event Collection Independent central raters blinded to treatment and visit number for primary outcome measure Dose-response in Phase 2b across "functionally active" doses Complementary studies with multiple 'functionally masking' arms Pre- and post-dose expectancy assessment (participants) Post-dose (participant) and rating (raters) blinding assessment Drug effect isolated from psychotherapeutic intervention Collection of ECGs in Phase 3 Clinical Trials Dedicated TQT study in parallel with Phase 3 Collection of all AEs, including "positive" and MOA-related Frequent assessment to define time course for resolution of drug effects Corporate Presentation \| August 2025

------

![Slide 28](mnmd-ex99_2s28.jpg)

+1y +2y +3y +4y +9y +5y +7y … 2043+ New Chemical Entity Exclusivity 30-Month Stay MM120 \| Multiple Layers of Intellectual Property and Protection Section 505 of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355. PK: pharmacokinetic; PD: pharmacodynamic MM120 Launch Potential Patent Protection Method of Use / Method of Treatment: Treatment of a Disorder Delivery: Delivery Method, PK / PD Drug Product: Method of Manufacture/Process API: Polymorph, Salt Form Supply chain availability Exclusive rights to key technology Lifecycle management with improved product performance Trade secrets & know-how Differentiated product performance Differentiated combination(drug and/or device products) Additional PotentialProtections Regulatory Protection1 Corporate Presentation \| August 2025